【レポートの概要（一部）】
Introduction 15
Drug Eluting Stents (DES) Overview 15
Products under Development 16
Drug Eluting Stents (DES) – Pipeline Products by Stage of Development 16
Drug Eluting Stents (DES) – Pipeline Products by Segment 17
Drug Eluting Stents (DES) – Pipeline Products by Territory 18
Drug Eluting Stents (DES) – Pipeline Products by Regulatory Path 19
Drug Eluting Stents (DES) – Pipeline Products by Estimated Approval Date 20
Drug Eluting Stents (DES) – Ongoing Clinical Trials 21
Drug Eluting Stents (DES) – Pipeline Products under Development by Companies 22
Drug Eluting Stents (DES) Companies – Pipeline Products by Stage of Development 22
Drug Eluting Stents (DES) – Pipeline Products by Stage of Development 24
Drug Eluting Stents (DES) Companies and Product Overview 27
Abbott Vascular Inc. Company Overview 27
Abbott Vascular Inc. Pipeline Products & Ongoing Clinical Trials Overview 27
Abbott Vascular Inc. – Ongoing Clinical Trials Overview 29
Absorb Bioresorbable Vascular Scaffold Clinical Trial Details 31
AlviMedica Medical Technologies Inc. Company Overview 40
AlviMedica Medical Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 40
AlviMedica Medical Technologies Inc. – Ongoing Clinical Trials Overview 42
Cre8 DES Clinical Trial Details 43
Amaranth Medical, Inc. Company Overview 45
Amaranth Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 45
Amaranth Medical, Inc. – Ongoing Clinical Trials Overview 47
FORTITUDE Scaffold Ongoing Clinical Trial Details 48
Next Generation FORTITUDE Scaffold Ongoing Clinical Trial Details 49
Arterius Ltd Company Overview 50
Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview 50
Biosensors International Group, Ltd. Company Overview 51
Biosensors International Group, Ltd. Pipeline Products & Ongoing Clinical Trials Overview 51
Biosensors International Group, Ltd. – Ongoing Clinical Trials Overview 53
BioFreedom Drug Coated Stent Clinical Trial Details 54
Excel II DES Ongoing Clinical Trial Details 55
BioSurfaces, Inc. Company Overview 56
BioSurfaces, Inc. Pipeline Products & Ongoing Clinical Trials Overview 56
Biotronik SE & Co. KG Company Overview 57
Biotronik SE & Co. KG Pipeline Products & Ongoing Clinical Trials Overview 57
Biotronik SE & Co. KG – Ongoing Clinical Trials Overview 60
Orsiro Hybrid Drug Eluting Stent Clinical Trial Details 61
Boston Scientific Corporation Company Overview 62
Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 62
Boston Scientific Corporation – Ongoing Clinical Trials Overview 65
SYNERGY Everolimus-Eluting Stent System Clinical Trial Details 66
CARDIONOVUM GmbH Company Overview 69
CARDIONOVUM GmbH Pipeline Products & Ongoing Clinical Trials Overview 69
CID S.r.l. Company Overview 71
CID S.r.l. Pipeline Products & Ongoing Clinical Trials Overview 71
Contego Medical, LLC Company Overview 73
Contego Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview 73
DISA Vascular (Pty) Ltd. Company Overview 74
DISA Vascular (Pty) Ltd. Pipeline Products & Ongoing Clinical Trials Overview 74
Elixir Medical Corporation Company Overview 75
Elixir Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview 75
Elixir Medical Corporation – Ongoing Clinical Trials Overview 80
DESyne BD Novolimus Eluting Coronary Stent System Ongoing Clinical Trial Details 81
DESyne Nx Novolimus Eluting Coronary Stent System Ongoing Clinical Trial Details 82
DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System Ongoing Clinical Trial Details 83
Envision Scientific Pvt. Ltd Company Overview 84
Envision Scientific Pvt. Ltd Pipeline Products & Ongoing Clinical Trials Overview 84
Eurocor GmbH Company Overview 85
Eurocor GmbH Pipeline Products & Ongoing Clinical Trials Overview 85
HangZhou HuaAn Biotechnology Co.,Ltd Company Overview 87
HangZhou HuaAn Biotechnology Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview 87
Icon Interventional Systems, Inc. Company Overview 88
Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 88
ICON Medical Corp. Company Overview 89
ICON Medical Corp. Pipeline Products & Ongoing Clinical Trials Overview 89
InspireMD, Inc. Company Overview 90
InspireMD, Inc. Pipeline Products & Ongoing Clinical Trials Overview 90
IRAMED GmbH Company Overview 92
IRAMED GmbH Pipeline Products & Ongoing Clinical Trials Overview 92
Lepu Medical Technology (Beijing) Co., Ltd. Company Overview 95
Lepu Medical Technology (Beijing) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 95
Lepu Medical Technology (Beijing) Co., Ltd. – Ongoing Clinical Trials Overview 97
Nano+ Stent Ongoing Clinical Trial Details 98
Medinol Ltd. Company Overview 99
Medinol Ltd. Pipeline Products & Ongoing Clinical Trials Overview 99
Medinol Ltd. – Ongoing Clinical Trials Overview 100
NIRsupreme Ridaforolimus-Eluting Coronary Stent System Clinical Trial Details 101
Medtronic plc Company Overview 102
Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 102
Meril Life Sciences Pvt. Ltd. Company Overview 104
Meril Life Sciences Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 104
Meril Life Sciences Pvt. Ltd. – Ongoing Clinical Trials Overview 108
BioMime Ongoing Clinical Trial Details 109
Micell Technologies, Inc. Company Overview 110
Micell Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 110
Minvasys Company Overview 112
Minvasys Pipeline Products & Ongoing Clinical Trials Overview 112
NanoCoeur, Inc. Company Overview 114
NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview 114
Northwestern University Company Overview 115
Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 115
OrbusNeich Company Overview 117
OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview 117
OrbusNeich – Ongoing Clinical Trials Overview 119
COMBO Dual Therapy Stent Clinical Trial Details 120
REVA Medical, Inc. Company Overview 122
REVA Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 122
Sino Medical-Device Technology Co., Ltd. Company Overview 125
Sino Medical-Device Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 125
Stentys, SA Company Overview 126
Stentys, SA Pipeline Products & Ongoing Clinical Trials Overview 126
Svelte Medical Systems, Inc. Company Overview 128
Svelte Medical Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 128
Tepha, Inc. Company Overview 130
Tepha, Inc. Pipeline Products & Ongoing Clinical Trials Overview 130
Terumo Corporation Company Overview 131
Terumo Corporation Pipeline Products & Ongoing Clinical Trials Overview 131
Terumo Corporation – Ongoing Clinical Trials Overview 134
Ultimaster Ongoing Clinical Trial Details 135
Tryton Medical, Inc. Company Overview 136
Tryton Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 136
University of Strathclyde Company Overview 138
University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview 138
VasoTech Inc. Company Overview 140
VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview 140
Xenogenics Corporation Company Overview 142
Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview 142
Zorion Medical Company Overview 144
Zorion Medical Pipeline Products & Ongoing Clinical Trials Overview 144
Drug Eluting Stents (DES)- Recent Developments 145
Mar 02, 2015: Tryton Medical Announces Publication of Data from Pivotal Trial for Tryton Side Branch Stent in Journal of American College of Cardiology 145
Feb 23, 2015: REVA Bioresorbable Program Update at CRT Conference 146
Feb 19, 2015: BIOTRONIK Advances Clinical Evaluation of Latest Generation DREAMS, World’s First Bioabsorbable Magnesium Scaffold 146
Feb 13, 2015: COMBO Dual Therapy Stent – Three-year Data featured at JIM 2015 147
Feb 12, 2015: Svelte Medical Systems and ASAHI INTECC Announce Manufacturing and Co-Branding Agreements 148
Feb 12, 2015: Biosensors Reports Financial Results for the Third Quarter of Fiscal Year 2015 148
Feb 09, 2015: LEADERS Free Japan Trial Completes Enrollment 150
Feb 04, 2015: Micell Technologies MiStent SES Now Commercially Available in Europe 151
Feb 04, 2015: BIOTRONIK Announces Completion of Patient Enrollment in BIOFLOW-IV Study Evaluating Safety and Efficacy of Orsiro 152
Jan 29, 2015: Abbott Reports Fourth-Quarter 2014 Results 152
Jan 23, 2015: MicroPort Receives CE Mark Approval for Firehawk 155
Jan 20, 2015: Mr. Aurelio Sahagun Promoted to COO of MicroPort Orthopedics 156
Jan 16, 2015: Eurocor Receives CE Mark Approval for E-Magic Plus SES 156
Jan 06, 2015: Biosensors Announces CTO’S Retirement 157
Jan 05, 2015: Acacia Subsidiary Enters into Settlement and Patent License Agreement with Cordis 157
Jan 04, 2015: Firehawk Gains CFDA Approval to Offer More Specifications 157
Dec 11, 2014: COMBO Dual Therapy Stent Healing Benefits Highlighted at GulfPCR-GIM 2014 157
Dec 03, 2014: REVA Implants First Patients With Fantom Scaffold 158
Dec 02, 2014: Terumo receives CE Mark approval for the line extension on Drug-eluting Stent, Ultimaster to advance the treatment of coronary artery disease 159
Nov 19, 2014: New Data From EVOLVE Clinical Program Demonstrate SYNERGY Bioabsorbable Polymer Stent Meets Key Performance Endpoints 159
Nov 12, 2014: Biosensors Reports Financial Results for the Second Quarter and First Half of Fiscal Year 2015 160
Nov 05, 2014: ClearStream Technologies Expands Enniscorthy Facility 162
Nov 04, 2014: Boston Scientific To Host And Webcast Investor Event 163
Nov 03, 2014: Micell Technologies Announces Plans for MiStent SES Commercial Launch 163
Nov 03, 2014: Medtronic Secures CE Mark For Resolute Onyx Drug-eluting Stent 164
Nov 03, 2014: STENTYS Expands Product Offering To All Coronary Stent Indications Through Exclusive Agreement With Micell To Distribute Its Novel Drug-Eluting Stent 164
Oct 27, 2014: STENTYS’ Sirolimus-Eluting Stent Receives CE Marking 165
Oct 20, 2014: Boston Scientific Initiates Study Of Promus PREMIER Coronary Stent System In Underserved Patient Populations 166
Oct 17, 2014: COMBO Dual Therapy Stent – A Long-term Solution to Vessel Restoration 167
Oct 10, 2014: BIOTRONIK to Offer New Treatment Options in France with Release of Orsiro Drug-Eluting Stent 167
Sep 18, 2014: Latest Data Shows OrbusNeich’s COMBO Dual Therapy Stent has Excellent Healing Benefits 168
Sep 18, 2014: World’s First Integrated Delivery System Meets All Endpoints in the Direct II Randomized, Controlled Drug-Eluting Coronary Stent Study 169
Sep 16, 2014: REVA Presents Fantom Scaffold Program at TCT 2014 Conference 170
Sep 16, 2014: Micell Technologies Highlights Positive Three-Year Data from MiStent SES DESSOLVE Clinical Studies at TCT 2014 170
Sep 16, 2014: Amaranth Medical Initiates Clinical Trial of the Second-Generation FORTITUDE Bioresorbable Drug-Eluting Scaffold 171
Sep 15, 2014: Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device 172
Sep 14, 2014: ABSORB II Study Shows Abbott’s Dissolving Heart Device Comparable to the World’s Leading Heart Stent 173
Sep 10, 2014: Tryton Medical Enrolls First U.S. Patient in the EXTENDED ACCESS Registry 174
Sep 10, 2014: Global Bifurcation Leader Tryton Medical Announces Events at TCT 2014 175
Sep 08, 2014: Elixir Medical Announces Schedule of Programs for TCT 2014 176
Sep 04, 2014: Initial Patient Enrolled in BioFreedom USA: First Major American Trial for Biosensors 177
Sep 03, 2014: STENTYS Reaches 10,000 Self-Apposing Stent implantations 178
Sep 01, 2014: BIOSCIENCE Trial Further Confirms Orsiro as Best in Class 178
Sep 01, 2014: Biosensors Welcomes New CEO 179
Aug 06, 2014: Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2015 179
Jul 28, 2014: Tryton Medical Enrolls First Patient in the EXTENDED Access Registry 181
Jul 16, 2014: First patient enrollment in MASCOT registry represents major milestone for COMBO Dual Therapy Stent and OrbusNeich’s clinical program 182
Jul 10, 2014: Abbott Builds Long Term Commitment In China 182
Jul 09, 2014: Micell Technologies Adds to Portfolio of Intellectual Property Protection 183
Jul 09, 2014: STENTYS Expands Marketing of the Self-Apposing Stent in South America 184
Jun 24, 2014: Abbott Announces Job Reductions At Lake County Headquarters In US 184
Jun 17, 2014: Biosensors Leaders Free Japan Trial Enrolls First Patient 185
Jun 12, 2014: First Patient Enrolled in Investigator Initiated REDUCE Study 185
Jun 02, 2014: Stentys Completes Acquisition of Cappella Peel Away from Cappella for USD1.4 Million 186
May 29, 2014: Svelte Medical Systems Announces Completion of 6-Month Follow-up in the DIRECT II Drug-Eluting Stent Study 186
May 28, 2014: Biosensors Reports Financial Results for Fiscal Year 2014 187
May 28, 2014: Biosensors Announces Appointment of New CEO 189
May 27, 2014: STENTYS Self-Apposing Stent Featured Prominently at 2014 EuroPCR Conference 189
May 23, 2014: OrbusNeich Releases Long-term Data for World’s First and Only Dual Therapy Stent 190
May 23, 2014: Micell Technologies Announces Positive Long-Term Data from MiStent SES Clinical Studies Presented at EuroPCR 2014 191
May 23, 2014: Elixir Medical Announces Clinical Trial Results of DESyne BD Novolimus Eluting Coronary Stent System at EuroPCR 192
May 23, 2014: Elixir Medical Announces Results for CE mark-approved DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System at EuroPCR 192
May 23, 2014: Elixir Medical Announces Outstanding Long-Term Clinical Results at EuroPCR for World’s Broadest Portfolio of Three CE Mark-Approved Novolimus Eluting Coronary Intervention Systems 193
May 22, 2014: REVA Holds Sponsored Symposium at EuroPCR 194
May 22, 2014: Complex Lesion BIOFLOW-III Subgroup Analyses Further Support Top Performance of BIOTRONIK Orsiro 194
May 21, 2014: Successful Live Case Demonstration of Elixir Medical’s CE Mark-Approved Fully Bioresorbable DESolve 100 Novolimus Eluting Coronary Scaffold System at EuroPCR 195
May 21, 2014: Boston Scientific Reports Strong Performance Data For SYNERGY Stent System 196
May 21, 2014: Biosensors Leaders Free Patient Population Data Presented at EuroPCR Enrollment Now Complete 196
May 21, 2014: Small Vessel BIOFLOW-II Subgroup Analyses Demonstrate Top Performance of BIOTRONIK Orsiro 197
May 20, 2014: STENTYS Sirolimus-Eluting Stent Demonstrates Best in Class Efficacy for Heart Attack Patients 198
May 15, 2014: Micell Technologies Announces Clinical Data from MiStent SES Studies Will Be Presented at EuroPCR 2014 198
May 14, 2014: Elixir Medical to Showcase a Live Case Demonstration of the Breakthrough Fully Bioresorbable DESolve 100 Novolimus Eluting Coronary Scaffold System at EuroPCR 199
May 13, 2014: Elixir Medical’s DESolve 100 Novolimus Eluting Coronary Scaffold System Gets CE Mark 200
May 06, 2014: STENTYS: Journal of the American College of Cardiology Publication Shows Malapposition Influences Death from Early Stent Thrombosis 201
May 05, 2014: USFDA Grants IDE Approval For Biosensors’ BioFreedom US Feasibility Trial 202
May 01, 2014: Boston Scientific Launches Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System In Japan 203
Apr 29, 2014: STENTYS’ Self-Apposing Stent Featured in New Article Published by the Journal of the American College of Cardiology 203
Apr 28, 2014: MicroPort Released New Products to its Nationwide Distributors 204
Apr 10, 2014: Abbott Completes Enrollment of Absorb Randomized Clinical Trials in the United States, Japan and China 204
Mar 28, 2014: Patient Enrollment Completed in Multicenter European REMEDEE Registry of OrbusNeich’s COMBO Dual Therapy Stent 205
Mar 27, 2014: Arterial Remodeling Technologies Enters Into Co-Development Agreement With Terumo For Bioresorbable Scaffold 205
Appendix 207
Methodology 207
Keywords: 209
About GlobalData 210
Contact Us 210
Disclaimer 210
【レポート販売概要】
■ タイトル：薬剤溶出ステントのグローバル製品パイプライン動向2015■ 英文：Drug Eluting Stents (DES) - Pipeline Review, 2015
■ 発行日：2015年3月20日
■ 調査会社：GlobalData
■ 商品コード：GDME0002EPD
■ 調査対象地域：グローバル
- 世界のLNG輸送市場2014Continuing weak demand and excess tonnage are expected to depress LNG shipping earnings in the near term. But longer term the sector could face vessel shortages as ordering slows and liquefaction projects come on stream. So to get a clear view of industry dynamics Drewry’s LNG market review takes a look back at the developments over recent years and then provides valuable forecast indicators, maki …
- ポリエチレン・テレフタレート(PET)の世界市場予測Polyethylene Terephthalate (PET) 2013 World Market Outlook and Forecast is an absolutely essential resource for anyone looking for detailed information on the mentioned market. Using a wide range of primary and secondary sources, we combined, analyzed and presented all available data about polyethylene terephthalate market in the all-in-one report issued in a logical and easily accessible format. …
- グローバルFMCG事業景況感サーベイ（2015年上半期）Summary “FMCG Business Confidence Report H1 2015” is a new report by Canadean that globally analyzes industry opinions on the latest economic and consumer issues, and their impact on investment decisions and growth prospects within the FMCG industry. This report also examines executive opinion about the current and future state of the economy and its retrospective effect on the industry. Furthermo …
- 院内感染検査の世界市場：UTI、SSI、肺炎球菌感染、血流感染、MRSAAbout Hospital-acquired Diseases Hospital-acquired diseases are also known as nosocomial infections that are acquired in hospitals and other healthcare facilities. These infections are classified only when a patient is admitted for reasons other than the infections and are caused by bacteria, fungi, parasites, or viruses. Most common types of hospital-acquired infections are SSIs, UTIs, bloodstrea …
- ニトロベンゼン(Nb)の世界市場予測Nitrobenzene 2014 World Market Outlook and Forecast is an absolutely essential resource for anyone looking for detailed information on the mentioned market. Using a wide range of primary and secondary sources, we combined, analyzed and presented all available data about nitrobenzene market in the all-in-one report issued in a logical and easily accessible format. In addition to the analytical part …
- 原油パイプラインの世界市場2016-2020About Crude Oil The crude oil processing cycle involves many stages to locate, develop, produce, and utilize the oil found underground. The overall petroleum value chain, based on these activities, is divided into the following broad segments: • Upstream • Midstream • Downstream Technavio’s analysts forecast the global crude oil pipeline market to reach 537.8 thousand miles of total length, during …
- 世界のSaaS型企業リソース計画ソフト市場動向（2012-2016）TechNavio's analysts forecast the Global Software-as-a-Service based Enterprise Resource Planning (SaaS-based ERP) Software market to grow at a CAGR of 13.93 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand from SMEs. The market has also been witnessing increased influence from social media and mobile apps. However, data security …
- エンジニアリングプラスチックの世界市場：PC、ABS、PET、PBT、POM、フッ素ポリマーThe market size for engineering plastics was estimated at 14,259 kilotons in 2014. In terms of value, Asia-Pacific was the largest market of engineering plastics, accounting for more than 40% of the global market and is projected to register a CAGR of 8.9% between 2015 and 2020. Europe accounted for the second-largest share of the global engineering plastics market in 2014. The demand for engineer …
- 糖尿病治療薬の世界市場2017-2021About Diabetic Therapeutic The global diabetic therapeutic market is growing at a high pace owing to the increase in the prevalence of diabetes globally. The top countries with high prevalence of diabetes are China, India, the US, Brazil, Russia, Mexico, Indonesia, Egypt, Japan, and Bangladesh. It is estimated that more than 1.5 million deaths occur due to diabetes worldwide each year. Technavio’s …
- 世界のポリシリコン市場動向（2012-2016）TechNavio's analysts forecast the Global Polysilicon market to grow at a CAGR of 14.30 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in solar energy consumption. The Global Polysilicon Market 2012-2016 has also been witnessing the decline in the price of Polysilicon. However, the oversupply in the industry could pose a challenge to the …
- 銀行向けアナリティクス及びリスク・コンプライアンスソリューションの世界市場2016-2020About Analytics and Risk Compliance Solutions Financial services, insurance, and banks are among the most data-driven industries. Commercial banks and insurance companies operate within regulatory environments that require firms to store and analyze several years of transactional data. For making the most from the business financial services, companies rely on relational technologies coupled with …
- オルソミクスウイルス感染症(Orthomyxoviridae Infections)：世界の治験レビュー2014年下半期版Orthomyxoviridae Infections Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Orthomyxoviridae Infections Global Clinical Trials Review, H2, 2014" provides data on the Orthomyxoviridae Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Orthomyxoviridae Infections. It includes an overview of t …
- 婦人科用医療機器の世界市場：製品別（ハンドヘルド機器、画像診断機器、外科用機器、ソフトウェア）、地域別、競合別、セグメント予測The global gynecological devices market size is projected to reach USD billion 17.55 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 8.8% during the forecast period. Growing female population, increasing awareness levels pertaining to benefits of early diagnosis, and available treatments are anticipated to stoke the growth of the market. Rising prevale …
- フランスの気道装置・麻酔装置市場France Airway and Anesthesia Devices Market Outlook to 2021 Summary GlobalData’s new report, "France Airway and Anesthesia Devices Market Outlook to 2021", provides key market data on the France Airway and Anesthesia market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market segments - Anesthesia Circuits, Anesthesia Masks, …
- フロック接着剤の世界市場予測（～2022年）：アクリル、ポリウレタン、エポキシ樹脂The global flock adhesives market is projected to grow from USD 2.35 Billion in 2017 to USD 3.18 Billion by 2022, at a CAGR of 6.3% in terms of value. Applications of flock adhesives are increasing due to the increasing requirement for bonding dissimilar materials, substituting traditional materials with synthetic substrates, and increasing focus on reducing VOC emissions. From an engineering and …
